linjc16/ctgov huggingface dataset:
Multimodal Music Therapy for Children With Anxiety Disorders

Study Overview
=================
Brief Summary
-----------------
Multimodal music therapy (MT) for children ages 8 to 12 years with anxiety disorders is compared to community treatment as usual (TAU). 36 children were randomized either to MT or to TAU. Primary outcome is presence of an anxiety disorder at the end of treatment. Secondary outcomes are self- and parent-/teacher reported anxiety, co-morbid psychological symptoms, and quality of life. Stability of outcome is assessed six months after the end of treatment.

Detailed Description
-----------------
Patients were enrolled in a community clinic and in an outpatient clinic for child and adolescent psychiatry/psychotherapy. Inclusion criteria: diagnosis of an anxiety disorder (separation anxiety disorder, general anxiety disorder, social phobia, specific phobia, or other anxiety disorder); age 8-12; no medication or stable medication during treatment; IQ>80; informed consent of caregivers and informed assent of patients. Outcome measures. Kiddie-SADS; STAIC-C, SPAIC, CDI; SDQ teacher report; CBCL 4-18; ILK quality of life inventory. Assessment time points: pre-intervention; post-intervention; 6-months follow-up.

Official Title
-----------------
A Randomized Controlled Trial of Multimodal Music Therapy for Children With Anxiety Disorders

Conditions
-----------------
Anxiety

Intervention / Treatment
-----------------
* Behavioral: Multimodal music therapy
* Behavioral: Community treatment as usual


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 8-12 years diagnosis of an anxiety disorder IQ>80 informed consent and assent Exclusion Criteria: anxiety disorder is not primary focus of treatment

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Multimodal music therapy<br>Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions. | Behavioral: Multimodal music therapy<br> <br> |
| Active Comparator: community treatment as usual<br> | Behavioral: Community treatment as usual<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of an anxiety disorder (DSM IV) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
music therapy, multimodal psychotherapy, children, anxiety disorders, pediatric anxiety
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Study Overview
=================
Brief Summary
-----------------
Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.

Detailed Description
-----------------
This study will evaluate a longer acting octreotide formulation. A subcutaneous implant at 2 doses will be evaluated for pharmacodynamics, efficacy and safety for a period of 9 months.

Official Title
-----------------
Open Label Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome

Conditions
-----------------
Carcinoid Syndrome

Intervention / Treatment
-----------------
* Drug: Octreotide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically confirmed tumor documented evidence of carcinoid syndrome life expectancy of at least 6 months previous positive octreotide scan received stable doses of octreotide injections performance status of 0-2 on the ECOG performance scale Exclusion Criteria: poorly differentiated or high grade neuroendocrine tumor significant cv, hepatic, renal or other disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1 implant<br>117 mg Octreotide implant | Drug: Octreotide<br>* short acting octreotide<br>|
| Experimental: 2 implants<br>234 mg Octreotide implant | Drug: Octreotide<br>* short acting octreotide<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the effects of 1 or 2 implants on carcinoid syndrome symptoms of flushing and diarrhea |  | 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety and tolerability of the implants |  | 9 months |
Non-invasive Diagnosis of Coronary Artery Stenoses by Doppler Echocardiography

Study Overview
=================
Brief Summary
-----------------
Non-invasive evaluation of patients with stable angina and unstable coronary syndromes with transthoracic Doppler echocardiography to evaluate presence of significant coronary stenoses. Blinded evaluation and comparison with coronary angiography: presence and location of stenoses, and head to head comparison of clinical value and patient classification.

Detailed Description
-----------------
Transthoracic Doppler echocardiographic evaluation with extensive evaluation of coronary stenoses in all 3 main branches using colour flow, pulsed Doppler and Coronary flow velocity reserve (CFVR)after pharmacologic stress with adenosin in the area of LAD and RDP. Blinded evaluation of Doppler results and coronary angiography regarding the other examination modality. Coronary angiography diagnostic gold standard. Only stable and unstable patients otherwise scheduled for angiography on clinical reasons will be examined and included in the study. Added January 2007 after ethics committee approval: comparison of CFVR with invasive fractional flow reserve (FFR) in selected subset of patients.

Official Title
-----------------
Non-invasive Evaluation of Coronary Pathology by Transthoracic Doppler Echocardiography. A Comparative Study to Coronary Angiography.

Conditions
-----------------
Stable Angina Pectoris, Unstable Angina Pectoris, Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Procedure: Doppler echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unstable angina or acute myocardial infarction, or stable angina pectoris and scheduled for coronary angiography on accepted clinical reasons Exclusion Criteria: past coronary artery grafting

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: transthoracic Doppler echocardiography<br> | Procedure: Doppler echocardiography<br>* Echocardiography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic yield: Accuracy, positive and negative predictive value. |  | Inhospital | 
| pr patient evaluation |  | Inhospital | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pr stenosis evaluation |  | Inhospital | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Doppler echocardiography, coronary stenosis, Coronary angiography
Venous Sinus Thrombosis : Clinical Picture and Outcome

Study Overview
=================
Brief Summary
-----------------
Cerebral venous sinus thrombosis (cvst) is an underdiagnosed neurological condition with variable clinical presentations and variable risk factors CVST is often an underdiagnosed cause of acute or slowly progressive neurological deficit. With increasing awareness of the entity and easy accessibility to the non-invasive test like CT and MRI scans,CVST cases are now being diagnosed more frequently and it is now thought to occur more commonly than previously assumed.it is also probably true that this condition is more frequent in underdeveloped countries

Official Title
-----------------
Venous Sinus Thrombosis : Clinical Picture and Outcome

Conditions
-----------------
Cerebral Vein Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to the neurology department and ER of an assuit university hospital with the diagnosis of venous sinus thrombosis accepting to participate in the study of both sex above 18 years and below 70 years Exclusion Criteria: 1. any case evident to have neurological deficit due to cause other than venous sinus thrombosis 2. patients refused to participate in this study 3-patients with uncertainty about her imaging study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cerebral venous sinus thrombosis | Clinical presentations of cerebral venous sinus thrombosis | 1 year |
Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms

Study Overview
=================
Brief Summary
-----------------
Patients with atypical symptoms of objectified gastroesophageal reflux disease will be treated by full-thickness gastroplication and the effect of this intervention will be measured by questionnaires and clinical diagnostics (for example pH/MII).

Official Title
-----------------
Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms.

Conditions
-----------------
Atypical Gastroesophageal Reflux Symptoms, Objectified Gastroesophageal Reflux Disease

Intervention / Treatment
-----------------
* Procedure: Full-thickness gastroplication (GERD-X)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 years and 80 years symptomatic, objectified reflux disease (atypical symptoms - Montreal-classification) Exclusion Criteria: Rejection of study-participation, Pregnancy negative pH-metry / impedance monitoring (non-objectified reflux) hiatal hernia bigger than 2 cm or gastroesophageal junction > Hill IV classification different potential reasons for atypical symptoms like heterotopic gastric mukosa in the cervikal esophagus Achalasia, esophageal spasm Presence of contraindications for the interventions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Atypical GERD syptoms treated with GERD-X<br>Patients treated by means of full-thickness gastroplication | Procedure: Full-thickness gastroplication (GERD-X)<br>* Endoscopic full-thickness gastroplication wit the GERD-X device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reflux Symptom index |  | 3 months |
Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.

Study Overview
=================
Brief Summary
-----------------
The outbreak linked to SARS-CoV-2 pandemic resulted in lock-down measures in almost all European countries. This online survey assesses these measures implications on Mental Health in emerging adults. The questionnaires evaluate two psychometric variables (Resilience and Loneliness) and Mental Health status (mental health professional help-seeking, use of psychotropic drugs, or possible diagnosis) before and during Lock-down Measures. At least 600 healthy participants aged form 18 to 25 years old will be attended to fill the survey during the SARS-CoV2 Pandemic Lock-down Measures.

Official Title
-----------------
Mental Health Implications During and After the COVID-19 Pandemic Lock-down Measures in Youth (18 - 25 Years Old) in French-Speaking Belgium and Italy: Resilience and Loneliness Evaluation.

Conditions
-----------------
Surveys and Questionnaires, Resilience, Psychological, Loneliness, Youth

Intervention / Treatment
-----------------
* Other: Survey and Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: French-speaking or Italian-speaking Subjects who accepted to participated to the online survey Inhabitants of a European country where SARS-CoV2 Pandemic Lock-down Measures are underway Survey filling date up to one week after the end of Lock-down Measures in the Country of residence Exclusion Criteria: Incomplete surveys

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Youth<br>Assessed group | Other: Survey and Questionnaire<br>* Resilience and Loneliness questionnaires<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-rated measure of Resilience | Measured with the Resilience Scale for Adults (RSA). | Up to 1 week after the end of the lock-down measures | 
| Self-rated measure of Loneliness | Measured with the UCLA (University of California, Los Angeles) Loneliness Scale. | Up to 1 week after the end of the lock-down measures | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mental Health, Emerging Adulthood
Effects of Celecoxib After Percutaneous Coronary Intervention

Study Overview
=================
Brief Summary
-----------------
Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Official Title
-----------------
Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial

Conditions
-----------------
Coronary Arteriosclerosis

Intervention / Treatment
-----------------
* Drug: Celecoxib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography Exclusion Criteria: Acute ST elevation MI Left main disease Contraindications to aspirin, clopidogrel or celecoxib Severe congestive heart failure Expected survival < 2 years Hepatic dysfunction Currently taking NSAIDs or any COX-2 inhibitor Renal dysfunction Use of warfarin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Active Comparator: Celecoxib<br> | Drug: Celecoxib<br>* celecoxib: loading and maintenance for 6 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Late luminal loss at 6 months |  | 6 months |
Application of Emergent Peripheral Mechanical Circulatory Support in Transcatheter Aortic Valve Replacement for 6 Patients

Study Overview
=================
Brief Summary
-----------------
Objective: To explore the experience of transcranial aortic valve replacement (TAVR) under emergency mechanical assisted circulation (MCS).Methods: A total of 6 patients who completed TAVR with the assistance of emergency MCS in the Second Affiliated Hospital of Zhejiang University School of Medicine from March 2013 to June 2019 were retrospectively analyzed.The management of perioperative mechanical assisted circulation, preoperative evaluation, intraoperative operation and postoperative situation of patients were summarized.

Official Title
-----------------
Application of Emergent Peripheral Mechanical Circulatory Support in Transcatheter Aortic Valve Replacement for 6 Patients

Conditions
-----------------
Transcatheter Aortic Valve Replacement, Mechanical Circulatory Support

Intervention / Treatment
-----------------
* Device: mechanical circulatory support


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: TAVR patient, assisted by emergency peripheral MCS due to circulatory collapse during TAVR Exclusion Criteria: patients presented mechanical complications such as massive hemorrhage, coronary artery occlusion or left ventricular rupture.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-Day mortality rate | 30-Day mortality rate | 30 days after TAVR procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transcatheter aortic valve replacement, mechanical circulatory support, cardiopulmonary bypass, ,extracorporeal membranous oxygenator
Impact of Women's Empowerment Program for Abused Pregnant Women

Study Overview
=================
Brief Summary
-----------------
Although domestic violence is recognized as major threat in pregnancy, there is no intervention has been developed or test to support women in India. To evaluate the effect of women's empowerment program administered to abused women in order to reduce domestic abuse, improving health status and safety behavior.

Official Title
-----------------
Impact of Women's Empowerment Program for Abused Pregnant Women: A Randomized Controlled Trial

Conditions
-----------------
Abuse Physical Battered Woman Syndrome

Intervention / Treatment
-----------------
* Behavioral: Empowerment Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years of age, victims of intimate partner violence, and willing to participate Exclusion Criteria: women whose abuser was not their intimate partner or who were unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Empowerment program<br>The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women. | Behavioral: Empowerment Program<br> <br> |
| No Intervention: Control group<br>Standard care, which was routine check ups and care provided by health care professionals. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life(Sf-36) |  | Five Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post natal depression |  | 5 months |